Transparency has been an objective in the pharma world in recent years, culminating in the recent decision by the EMA to release full clinical study reports into the public domain. In spite of the publicity surrounding transparency and data sharing in pharma, the world of medical devices has largely flown under the transparency radar, but change is on the way. The final text of the long-awaited Medical Device Regulation was published in late February, and jumped the final hurdle of adoption by the European Parliament in April. This overhaul was prompted by scandals surrounding silicone gel breast implants and metal-on-metal hip replace - ments in the early 2010s that highlighted the lack of oversight and transparency. So why is this important and what are the implications for transparency?
Van Norman GA. Drugs and Devices: Comparison of European and U.S. Approval Processes. JACC: Basic to Translational Science. 2016; 1(5): 399–412
Available from: http://
Posting of clinical trial summary results in European Clinical Trials Database (EudraCT) to become mandatory for sponsors as of 21 July 2014 [cited 2017 Mar 13]
Available from: http://europa.eu/ rapid/press-release_IP-10-443_en.htm
Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals [cited 2017 Mar 09]
Available from: http://www.icmje.org/icmje-recommendations.pdf
Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen JM, et al. Sharing clinical trial data: A proposal from the International Committee of Medical Journal Editors. Ann Intern Med. 2016 Apr 5;164(7):505-6
Available from: http://